Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Richard Edmondson, Frances Balkwill, David Bowtell, Steffen Boehm, Ahmed Ahmed, Paul-Joseph Aspuria, Valerie Beral, Jonathan Berek, Mike Birrer, Sarah Blagden, Michael Bookman, James Brenton, Katherine Chiappinelli, Filipe Correia Martins, George Coukos, Ronny Drapkin, Christina Fotopoulou, Hani Gabra, Jerome Galon, Charlie GourleyValerie Heong, David Huntsman, Marcin Iwanicki, Beth Karlan, Allyson Kaye, Ernst Lengyel, Douglas Levine, Karen Lu, Iain McNeish, Usha Menon, Steve Narod, Brad Nelson, Kenneth Nephew, Paul Pharoah, Daniel Powell, Pilar Ramos, Iris Romero, Clare Scott, Anil Sood, Euan Stronach

Research output: Contribution to journalArticlepeer-review


High-grade serous ovarian cancer (HGSOC) accounts for 70–80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.
Original languageEnglish
Pages (from-to)668–679
Number of pages12
JournalNature Reviews. Cancer
Issue number11
Early online date23 Oct 2015
Publication statusPublished - 1 Nov 2015

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer'. Together they form a unique fingerprint.

Cite this